Despite progress in cardiovascular research, cardiac pathology continues to be one of the most common causes of morbidity and mortality in the world. Stem cell-based therapy has been recognized as an innovative strategy for the repair, regeneration and functional recovery of the myocardium, hence, once the animal research stage has been overcome, most clinical trials aimed at evaluating the safety and effectiveness of regenerative medicine in cardiovascular diseases have focused on angina pectoris, myocardial infarction and chronic cardiomyopathy. Although the current evidence of benefit is not conclusive, the evidence in favor of favorable results is growing.
In some cases, stem cell therapy can provide an effective treatment or alternative for diseases or disorders for which there is no effective treatment. Because these cells are capable of dividing into a wide range of lineages and tissues, they can be used to treat various diseases by repairing, replacing, and regenerating tissues.
It is unclear how umbilical cord mesenchymal stem cells act on the heart, but previous studies have shown that they possess an anti-apoptotic effect. The induced cardiomyocytes can form discs interspersed with myocytes from the host cells, creating a functional syncytium that will help contract the heart. Mesenchymal stem cells can improve cardiac function and reduce damage caused by cardiovascular disease, since they stimulate endogenous repair mechanisms, the regulation of the immune response, tissue perfusion and the proliferation of the resident heart rate, thereby improving cardiac function and reducing damage severity.
This syndrome, characterized by persistent angina despite standard medical treatment, is often not revascularized due to diffuse coronary lesions or severe comorbidities.
In 2017, a review included 13 clinical studies, with 1061 patients and 12 months of follow-up on average, indicating cell therapy has emerged as a tool for managing these patients. Although the available data are inconclusive, the authors conclude that stem cell-based therapy could be a viable addition to conventional treatment options for refractory angina, given the paucity of therapeutic alternatives.
There was a reduction in mortality at two years after a meta-analysis in 2018, involving 304 patients, showed improved exercise tolerance and reduced angina attack frequency at three, six and 12 months. An additional meta-analysis published in March 2019, involving 526 patients monitored for 14 months, showed that patients treated with stem cells had fewer serious adverse effects, fewer deaths, fewer angina attacks, and fewer antianginal medications than those treated with conventional management.
A third meta-analysis from 2019, with 269 patients and 15 months of follow-up on average, reports the following results: decreased all-cause mortality, decreased frequency of angina and increased exercise time, with no increase in adverse reactions.
Cardiomyopathy (ischemic and non-ischemic)
Despite optimal medical and surgical management, many patients with heart failure undergo long-term myocardial remodeling that does not allow them to restore their ventricular function. This is because current treatment protocols cannot reverse the loss of cardiomyocytes due to cardiomyopathy. Since inflammatory responses continue over time as a central mechanism in the development of heart failure, it was of interest to investigate the anti-inflammatory, antifibrotic, and immunomodulatory properties of stem cells in patients with ischemic and non-ischemic cardiomyopathy.
In a review of five clinical studies published between 2017 and 2018, including 605 patients, the authors conclude that cell therapy is safe, causes immunomodulatory effects, improves functional capacity, and adds clinical benefits to standard therapies. According to them, the results are promising, and further evidence strengthening is recommended.
Based on a meta-analysis published in May 2019, involving 20 investigations and 1418 patients evaluated for an average of 21 months, stem cells improved cardiac function indicators (LVEF and LVESV), walking distance, functional classification of heart failure, quality of life, and mortality as compared to controls. Hospitalizations and serious adverse events were not different from those in the control group.
In a recent review of 9 studies involving 612 patients with heart failure, improvement was found in clinical and paraclinical parameters, evaluated on average for 9 months. According to the authors, stem cells are an effective therapy for the treatment of heart failure, improving patient prognosis and ability to exercise.
Acute myocardial infarction (AMI)
The application of stem cells was associated with a significant increase in left ventricular ejection fraction (LVEF) and other variables indicative of improved ventricular function and modification of remodeling in patients with AMI receiving timely percutaneous coronary intervention (PCI) and conventional medication in different studies. Even coronary artery bypass grafting with stem cells offers greater benefits. A number of studies have also shown that intravenous administration could be a more efficient and effective method of treating the heart or coronary arteries than direct application, with logistic, safety, and cost advantages.
Stem cell therapy is evidenced to be a safe way to treat cardiovascular diseases, as it shows an anti-apoptotic effect, reduction of lesion size, improvement of cardiac function through regulation of the immune response, adequate tissue perfusion and activation of growth factors.
We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
Atherosclerosis is the most common form of arterial occlusive disease in adults. About 15 percent of adults over 55 years of age suffer from critical ischemia, the most severe form of this disease.
Due to the gradual aging of the population and the growing number of people in their third age group, a number of studies have been conducted in order to improve the prognosis of atherosclerosis obliterans and to find alternatives to the mutilation of the extremities. As a general rule, chronic ischemia of the lower limbs should be treated to alleviate symptoms, particularly pain, prevent disease progression, and reduce the rate of amputations. In most patients with critical ischemia, the main goal is to preserve the affected limb.
The development of regenerative medicine is closely linked to the development of new knowledge about embryonic and adult stem cells, as well as the regenerative and therapeutic potential of stem cell therapy. The use of adult stem cells in the treatment of peripheral artery diseases has been demonstrated as a therapeutic agent for inducing angiogenesis. Recent preclinical studies as well as the pioneering clinical studies indicate that bone marrow-derived mononuclear cells (MBMCs) can enhance tissue vascularization in ischemic limbs, with results similar to those obtained with peripheral blood stem cells supply.
Cuba presented the first studies carried out in 2004 at the Institute of Hematology of the “Enrique Cabrera” hospital in Havana City, which achieved encouraging clinical results and had very few adverse effects in recent years.
A progressive rise in the accumulated experience with stem cells was also observed in Pinar del Rio in 2005, as the first 10 cases were carried out. The rising ease of obtaining this type of cell has made research and applications with these cells advance rapidly with great expectations in terms of clinical application.
A study published by Dia-Diaz, et al. in the Journal of Medical Sciences of Pinar del Rio examined 296 patients with grade IV atherosclerosis obliterans between 2009 and 2019. During the study, autologous stem cells were injected intramuscularly from peripheral blood. Within four weeks, pain relief was observed, as well as an increase in the pain-free claudication distance. Angiography after treatment revealed collateral vessel formation. The limb was saved in 201 patients (68%), while 95 cases (32%) presented amputation criteria. Complications were not reported following the procedure.
The study demonstrated the effectiveness of the implantation of autologous stem cells obtained from peripheral blood, as well as the favorable evolution of patients, clinical improvement of rest pain, walking distance without claudication and ankle-brachial pressure index.
We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
In recent years, MSCs have been introduced as respectable candidates for regenerative medicine due to their pro-angiogenic, anti-apoptotic, and immunomodulatory attributes. A variety of human tissues can be used as a source of mesenchymal stem/stromal cells (MSCs), ranging from bone marrow (BM) to umbilical cord (UC). These cells are typically multipotent and can differentiate into a variety of cell types. MSCs have been studied extensively for potential applications in cardiomyopathy, neurodegenerative disorders, spinal cord injuries (SCI), kidney injuries, liver injuries, lung injuries, and even cancer. According to current research, MSC-derived extracellular vesicles (EVs) contribute to MSC-exerted therapeutic benefits.
As defined by the International Society for Extracellular Vesicles (ISEV), EVs are lipid bilayer particles secreted by cells that do not replicate. EVs can be categorised into three subclasses based on size and biogenesis procedures: surrounding exosomes (50-150 nm), microvesicles (MVs) (100-1000 nm), and apoptotic bodies (ApoBDs) (500-5000 nm). In order for exosomes to be produced, multiple steps must occur; endosomes must be created from the plasma membrane, intraluminal vesicles must be formed within multivesicular bodies by inward budding, the MVB must merge with the plasma membrane, and finally the internal vesicles must be released.
By transmitting their molecules, such as proteins, messenger RNA (mRNA), and microRNAs (miRNAs), MSC exosomes stimulate phenotypic changes and subsequently modify regenerative programs of target organs. A number of mechanisms are involved in phenotypic alterations, including prevention of apoptosis, cell proliferation, immunomodulatory reactions, attenuation of oxidative stress, and improving oxygen supply to recipient cells. By supporting mitochondrial transfer, MSC-exosomes can suppress inflammatory cytokine production and induce phenotype 2 alveolar macrophages (M2), leading to acute lung injury (ALI) rescue. It has been demonstrated that the transmission of miRNAs from MSC-exosomes to recipient cells is responsible for the restoration of damaged kidneys, hearts, livers, and brains
Various cells continuously form and secrete exosomes, including lymphocytes, platelets, mast cells, intestinal epithelium, dendritic cells, neoplastic cell lines, microglia, neurons, and MSCs. Studies have shown that exosomes play an important role in cell-to-cell communication as well as several physiological and pathological processes. Despite their inherent biological activities, exosomes have recently been introduced as encouraging drug carriers because of their small size, high biocompatibility, and ability to hold different therapeutic ingredients, including proteins, nucleic acids, and small molecules. There have been reports showing the usefulness of MSCs-exosomes for treating a variety of ailments, such as lung, kidney, liver, neurodegenerative, cardiac, and musculoskeletal diseases, as well as skin wounds in vivo.
As well as their remarkable therapeutic effects, MSC-EVs derived from diverse sources also possess a variety of physiological functions that may affect their therapeutic application. In a wide range of human disorders, MSC-exosomes are considered an effective alternative to whole-cell therapy because of their low immunogenicity and improved safety profile. Although MSC-exosome applications still face various challenges, their benefits and capabilities are attracting increasing interest.
To learn more about exosomes and their clinical applications or if you’re interested in boosting your clinical practice with exosomes, go to our website www.cellgenic.com
Stem cell therapy is a form of regenerative medicine designed to repair damaged cells within the body by reducing inflammation and modulating the immune system. This phenomenon makes stem cell therapy a viable treatment option for a variety of medical conditions.
What is stem cell therapy?
The term stem cell therapy refers to any treatment involving the use of viable human stem cells including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and adult stem cells. By being able to differentiate into the specific cell types necessary for repairing diseased tissues, stem cells are the ideal solution for tissue and organ transplantation.
As stem cell-based therapies are complex, researchers often seek stable, safe, and readily available sources of stem cells that can differentiate into multiple lineages. As such, choosing stem cells with clinical applications in mind is of the utmost importance
The hierarchy of stem cells
In general, stem cells fall into three categories. In addition to self-renewal, all three share a unique ability to differentiate. However, stem cells do not exist in a homogeneous form, but rather in a developmental hierarchy. Among all stem cells, totipotent cells are the most basic and least developed. These cells are capable of developing into a complete embryo while forming the extraembryonic tissue at the same time. During the fertilization of the ovum, this unique property begins and ends when the embryo reaches the stage of four to eight cells.
As the cell divides further, it loses its totipotency property and becomes a pluripotent cell, capable of dividing into each of the three embryonic germ layers (ectoderm, mesoderm, and endoderm). These cells are referred to as “embryonic stem cells” and are isolated from the inner cell mass of the blastocyst after the embryo is destroyed.
The property of pluripotency is lost with successive divisions, resulting in a more limited differentiation capability in which the cells can only differentiate into limited types of cells related to their origins. “Adult stem cells” have this property, which helps maintain homeostasis throughout the organism’s lifespan. It is known that adult stem cells are present in most specialized tissue types of the body in a metabolically quiescent state, including bone marrow and oral and dental tissue.
According to many authors, adult stem cells are the gold standard for stem cell-based therapies. A number of trials involving adult stem cells have shown promising results, especially in the transplantation of hematopoietic stem cells.
Stem cell research for treating disease
In 2006, Shinya Yamanka achieved a scientific breakthrough in stem cell research by generating cells with the same properties as embryonic stem cells. In fully differentiated somatic cells, namely fibroblasts, four transcription factors were transiently over-expressed, including OCT4, SOX2, KLF4, and MYC. As a result of the discovery of these cells, stem cell research has been transformed ever since. Similar to embryonic stem cells, these cells are capable of dividing into any of the germ layers. As a result of the development of iPSC technology, disease identification and treatment have become more innovative. IPSCs are therefore promising as a source of pluripotent derived patient-matched cells that can be used for autologous transplants because they can be generated from the patient’s own cells.
It is believed that stem cells, due to their unique capacity to regenerate, may hold new potential for treating diseases such as diabetes and heart disease. Despite this, there remains much work to be done in the laboratory and clinic to determine how these cells can be used in regenerative or reparative medicine to treat diseases.
Studies of stem cells in the laboratory allow scientists to gain a better understanding of the cells’ essential properties as well as what makes them different from specialized cell types. Researchers are already using stem cells to test new drugs and develop model systems for studying normal development and identifying the causes of birth defects in the laboratory.
The study of stem cells continues to advance our understanding of the development of an organism from a single cell and of how healthy cells replace damaged cells in adult organisms. Research on stem cells is one of the most fascinating areas of contemporary biology, but, as with many fields of science that expand rapidly, it raises as many questions as it answers.
To learn more about stem cells, cellular therapies and new medical protocols using exosomes sign up for our international certification in regenerative medicine at www.issca.us
The XXV Congreso Internacional de Medicina, Cirugia Estética y Obesidad will take place in CDMX, México on July 13,14 and 15, 2022. The International Society for Stem Cell Application (ISSCA) will be actively taking part in the congress. The ISSCA is a multidisciplinary community of physicians and scientists with a mission to advance the science, technology, and practice of regenerative medicine to treat diseases and lessen human suffering through science, technology, and regenerative medicine. Several ISSCA members will be presenting or giving demonstrations on the latest protocols and technologies in regenerative medicine.
- Benito Novas, the managing director of the ISSCA from the USA, will give a talk about Digital Marketing in Cash-Based Practices. Benito Novas is a global entrepreneur, manager, and keynote speaker, who specializes in marketing focused on biotechnology, life sciences, and healthcare development. He has served as the director of the ISSCA since 2016. His published books in Aesthetic Practice and Digital Marketing can be found here. In his presentation this July, he will share his visionary approach to healthcare management and regenerative medicine. Congress attendees will have the opportunity to learn why doctors must use digital marketing strategies to grow a successful practice. Benito Novas will provide tips to attendees on how to capitalize on social media trends to grow practice influence.
- Dr. Maritza Novas, the ISSCA director of education from the USA, will talk about Allogeneic Therapies and Stromal Cell Exosomes. The use of allogeneic therapy is one of the most attractive alternatives to autologous products and is of utmost interest to researchers in recent years. Exosomes serve as mediators for cell-to-cell communication and can be used as cell-free therapeutics for their special characteristics. Dr. Maritza Novas has been in aesthetic and anti-aging medicine since 2001. She is globally recognized for her work in regenerative medicine and dedicated service in education.
- Dr. Silvina Pastrana, the Argentina chapter director of the ISSCA from Argentina, will present on Fundamentals of Cellular Therapies and Mesenchymal Stem Cells (MSC). Dr. Pastrana heads a staff of medical specialists in orthopedics, rheumatology, medical clinic, and cosmetic surgery, performing procedures that incorporate stem cell therapies. She has been serving as a staff surgeon for the Hospital Dr. Prof. Luis Güemes for 21 years.
Besides the above presentations, look forward to sessions in the practical portion of the congress, where the following ISSCA members will show the latest protocols and technologies in regenerative medicine:
- Dr. Julio Ferreira (Argentina), Cosmetic Surgery / Aesthetic Medicine
- Dr. Andrea Lapeire (Argentina), Aesthetic Medicine
- Dr. Maritza Novas (USA), ISSCA Director of Education in the USA
- Dr. Silvina Pastrana (Argentina), Chapter Director of ISSCA in Argentina
The ISSCA members are the leaders in setting standards and promoting excellence in the field of regenerative medicine, related education, certification, research, and publications. The Global Stem Cells Groups (GSCG) is a group of companies, including the ISSCA and other members, dedicated to facilitating stem cell research and medicine. Making the benefits of stem cell medicine a reality for both doctors and patients worldwide is the goal of the GSCG. To learn more, visit our sites at the ISSCA and the GSCG.
Exosome therapy is the new buzz in the regenerative medicine industry because of how it can repair and regenerate your cells and tissues.
Exosome therapy is safer compared to other cellular therapy because it’s a cell-free therapy with no risk of rejection.
Exosome therapy will be beneficial to you if you’re dealing with conditions such as sport injuries, tissue regeneration, hair loss, erectile dysfunction, chronic pain and so many other applications .
In this article, you’ll be learning the cost of exosome therapy and how you can benefit from exosome therapy.
How the cost of exosome therapy is determined
All cells produce exosomes, which are microvesicles that contain biochemical and genetic information.
Hence, the cost of an exosome product (used in exosome therapy) will depend on what type of cell line (raw tissue source) used to extract the exosomes.
The first factor to determine the cost of an exosome product depends on the quality of the tissue source.
The most commonly used tissue types are cord blood, amniotic fluid and mesenchymal cell cultures.
Exosomes derived from mesenchymal cell cultures are the most difficult to obtain but offer the greatest therapeutic potential.
How much does exosome therapy cost?
The average cost of exosome therapy is $4,900, but the price can be anything from $3,500 – $6,500.
It’s also important to note that the price depends on your specific needs and your treatment plan, as decided by the doctor.
The doctor will schedule a consultation with you to determine your personalized treatment plan.
The exosome therapy can either be given as an IV infusion or as localized injections, depending on the purpose of the therapy.
Exosomes are very useful to revitalize, rejuvenate, restore, and reduce inflammations in the body.
Here are some ways you can benefit from exosome therapy
Hair loss therapy: If you’re in the early stages of hair loss, with exosome therapy you can regenerate your hair whether you’re a man or woman. After exosome therapy, you’ll start seeing new hair growth in as little as two to three months with very significant results showing 6 months or 1 year later.
Chronic pain: In case you’re experiencing chronic pain due to degenerative conditions such as arthritis, exosomes can help to subdue the pain by regenerating the cells and helping the body work better.
Degenerative conditions: If you’re struggling with degenerative medical conditions such as osteoarthritis and musculoskeletal injuries, exosome therapy can help your body repair the damage done to your cells by these conditions, prevent them from getting better, and help you to feel better.
Skin therapy: exosome therapy can reduce inflammation in the skin by improving the strength and elasticity of the skin.
Anti-aging: if you would like to retain your youthful glow, exosome therapy can make you feel young again by rejuvenating your skin due to its ability to reverse the cells dying due to aging.
Where can you get exosome therapy?
Cellular hope institutes provide exosome therapy for patients looking for better outcomes for various conditions.
The exosomes used at Cellular Hope Institute are obtained from umbilical cord tissue that is discarded after a new birth , which means these Exosomes have not been exposed to any contaminating or toxic agent because our cells are as healthy as our body. This gives it a higher capacity to regenerate your cells and tissues.
Mesenchymal Stem Cells (MSCs) are the most commonly used cells in stem cell therapy and regenerative medicine, due to their high and multi-potency. Mesenchymal Stem Cells (MSCs) can be isolated from different tissues in the body.
In this article, you’ll be learning about culture-expanded MSCs, how MSCs can be expanded, The potency of MSCs and the type of cells they can differentiate into.
What are culture expanded Mesenchymal Stem cells?
Mesenchymal stem cells are high potent cells used for cellular therapy and isolated from different parts of the body. Mesenchymal stem cells can be used to improve the patient outcome in diseases and conditions such as autoimmune diseases, degenerative diseases, nerve damage, diabetes mellitus, bone problems etc.
For every patient, millions of mesenchymal stem cells are needed and the exact amount varies according to disease, route of administration, administration frequency, weight, and age of patient.
Mesenchymal stem cells are expanded in a culture media, on a large scale in order to obtain the required quantity of cells needed for cellular therapy.
Culture expanded MSCs: How does it work?
Expanding Mesenchymal stem cells in a media involves step by step process of isolation and expansion.
Mesenchymal Stem Cells Isolation
Mesenchymal stem cells can be isolated from different tissues in the human body such as adipose tissues, dental pulp, human bone marrow, umbilical cord tissue, umbilical cord blood, peripheral blood and synovium.
Mesenchymal stem cells are expanded in culture to increase their yield and amplify their desired functions and potency.
Although the population of Mesenchymal Stem Cells obtained will vary from donor to donor, here are some steps to follow:
· Acquire fresh tissue extracts in strictly aseptic conditions, to maintain purity.
· To remove any cell clusters, you have to filter the cell suspension with a 70-mm filter mesh
· Use a centrifuge to roll the cells for about 5 minutes at 500g
· Suspend the cells again the cells to measure the cell viability and yield using Trypan blue exclusion
· Use in T75 culture dishes to culture the cells in 10 mL of complete MSC medium at a density of 25 × 106 cells/mL. You can then go on to Incubate the plates at 37 °C with 5% CO2 in a humidified chamber without any interruption.
· When it’s past 3 h, remove the non-adherent cells that accumulate on the surface of the dish by changing the medium and replacing it with 10 mL fresh complete medium.
· After an additional 8 h of culture, add 10ml fresh complete medium as a replacement for the existing medium. You’ll have to repeat this step every 8 h for up to 72 h of initial culture.
· Cells can be frozen in MSC growth media plus 10% DMSO (D2650) at a density of 2X106 cells/vial.
Expansion of Mesenchymal Stem Cells in a culture media
Culture expanded mesenchymal cells undergo various stages from the preparation of the culture plate, thawing of Mesenchymal stem cells, and the actual expansion of Mesenchymal stem cells.
The reason behind the cultural expansion of Mesenchymal stem cells is to get them to differentiate into other cell types such as osteoblast, adipocyte, and mesenchymal stromal cells.
In preparation, to expand MSCs in a culture media, you need a culture ware. You can get one plastic or glassware plate and coat it with a sufficient amount of 0.1% gelatin. Don’t forget to aspirate the gelatin solution from the coated plate or flask before you use it.
The next step involves the thawing of the Mesenchymal stem cells, and here are a few steps for you to follow:
After the recommended culture medium and coated culture ware is ready and on standby, remove the vial of Mesenchymal Stem Cells from liquid nitrogen and incubate in a 37C water bath and pay close attention to it, until all the cells are completely thawed. The extent of completely thawed frozen cells and how fast, are what determines the cell viability.
Once the cells have thawed completely, take steps to avoid contamination by disinfecting the walls with 70% ethanol, before you proceed to the next step.
Place the cells in a hood, and carefully transfer the cells to a sterile tube with a pipette (1 or 2ml pipette), Do this in such a way to prevent bubbles.
Then, add drops of Mesenchymal Stem cell expansion medium that have been pre-warmed to 37C to the tube containing the Mesenchymal stem cells.
Be careful to take your time when adding the medium to avoid osmotic shock which could lead to decreased viability.
Proceed to mix the suspension slowly by pipetting up and down two times while avoiding any bubbles.
Place the tube in a centrifuge and centrifuge the tube at 300 x g for 2-3 minutes to roll the cells, and you should not vortex the cells.
After this, then decant as much of the supernatant as possible. These steps are necessary to remove residual cryopreservative (DMSO).
Suspend the cells in a total volume of 10 mL of Mesenchymal Stem Cell Expansion Medium again or any alternative of choice, pre-warmed to 37 °C, containing freshly added 8 ng/mL FGF-2 (F0291).
The next step involves placing the cell suspension onto a 10-cm tissue culture plate or a T75 tissue culture flask.
Maintain the cells in a humidified incubator at 37 °C with 5% CO2.
The next day, exchange the medium with fresh Mesenchymal Stem Cell Expansion Medium (pre-warmed to 37 °C) containing 8 ng/mL FGF-2*. Replace with fresh medium containing FGF-2 every two to three days thereafter.
Isolate the cells when they are approximately 80% confluent, using Trypsin-EDTA and passaged further or frozen for later use.
Expansion of Mesenchymal Stem Cells
Once the cells are actively proliferating and have reached a confluence of approximately 80% (before 100%), you should subculture the cells.
Then remove the medium from the 10-cm tissue culture plate containing the confluent layer of human mesenchymal stem cells, carefully and apply 3-5 mL of Trypsin-EDTA Solution, before proceeding to incubate in a 37 °C incubator for 3-5 minutes.
Crosscheck the culture to see if all the cells are completely detached. Then, add 5 mL Mesenchymal Stem Cell Expansion Medium to the plate.
Swirl the plate mildly to mix the cell suspension. Transfer the separated/isolated cells to a 15 mL conical tube.
Centrifuge the tube at 300 x g for 3-5 minutes to pellet the cells.
Throw the supernatant away and apply 2 mL Mesenchymal Stem Cell Expansion Medium (pre-warmed to 37 °C) containing 8 ng/mL FGF-2 to the conical tube and completely suspend the cells again. Remember not to vortex the cells.
Then, use a hemocytometer to count the number of cells.
Plate the cells at a density of 5,000-6,000 cells per cm2 into the appropriate flasks, plates, or wells in a Mesenchymal Stem Cell Expansion Medium containing 8 ng/mL FGF-2.
Cells can be frozen in MSC growth media plus 10% DMSO (D2650) at a density of 2X106 cells/vial.
Functions of Culture Expanded MSCs
Mesenchymal stem cells are required to be expanded in order for them to be used clinically for therapeutic purposes.
The culture expanded MSCs can be induced to differentiate into adipocytes, osteocytes, hepatocytes, chondrocytes, tenocytes and cardiomyocytes.
Because of its potential to differentiate into different kinds of cells in the body, it can be used to manage liver problems, heart problems, joint and bone problems etc.
Mesenchymal stem cells are also used in tissue regeneration and modulation of the immune system. They possess anti apoptotic, angiogenic, anti fibrotic, and anti-oxidative properties.
However, the quantity of MSCs isolated from body tissues is not enough for clinical and therapeutic applications.
This is why MSCs are expanded in culture to increase their yield for desired therapeutic effect.
Are you a physician that is currently utilizing adipose tissue, but is growing tired of the time-consuming, arduous procedure? Are you having problems finding reagents that allow you to isolate stem cells? If so, GCell might be the solution for you.
What is GCell?
GCell is a revolutionary new machine that holds the potential to become the future of adipose stem cell processing. This is due to a variety of reasons, from the compactness of the unit, to its short processing time– it truly is a valuable implement in any regenerative medicine practitioner’s office. GCell employs a process of mechanical breakdown, which in addition to shortening the duration of the treatment, also serves to keep it within legal minimal-manipulation regulations.
How Does GCell Work?
Through a system of extremely small blades and filters, it is able to homogenize a sample of fat taken from anywhere in the body, making it into a slurry of growth factors, proteins, and the other components that make up the sample. The GCell then filters out the stromal vascular fraction cells, and uses a process called photoactivation to increase their vitality. Once the process is over, the end result is a final product that can be administered to patients within forty minutes from the sample’s harvesting. This is a far cry from the previous, muti-hour long treatments that physicians have grown accustomed to, and this shortened timespan is something that both doctors and their patients will greatly appreciate.
Additionally, it is a single-session treatment. This means that patients that wish to receive a GCell treatment will only have to visit their clinic once, and will not have to undergo any followup treatments. This machine provides the convenience of its small size and lightweight build with the ability to accelerate the stem cell harvesting process– but that isn’t all. The GCell has been designed to be an entirely enclosed system– this is important, as it means that samples that are run through the GCell will remain in a sterile environment, which preserves the viability of samples and ensures positive outcomes for patients.
The GCell combines a grinder, a filter, and a photoactivation device, and is a turnkey solution that can take a physician from harvesting a fat sample to administering an injectable regenerative medicine therapy in less than an hour. GCell has been designed to be especially useful for clinics that are just beginning to implement regenerative medicine into their practice, but it’s all inclusive approach to stem cell isolation is what sets it a cut above the rest.
GCell’s Single Session Treatment Protocol
Unlike many other cellular therapies on the market, it is a single-session treatment, which means that there is no need for the patient to come back after his original treatment day has ended. This machine’s portability, small stature, and ability to accelerate the stem cell harvesting process makes it ideal for clinics that are just beginning to implement regenerative medicine into their practices, as it takes much of the rigor out of adipose-derived stem cell harvesting.
The International Society for Stem Cells Applications has officially announced and published its list of speakers for its 7th Annual Regenerative Medicine Symposium. The seventh event of its kind, it is another effort from the iSSCA to bring together a network of regenerative medicine practitioners from all over the world. At previous events, hundreds of physicians came to share in their knowledge regarding cellular therapies and the patients whose lives they can change, and the aim of this year is no different– of course, as a reunion of medical professionals, several steps will be taken to ensure proper social distancing measures, as well as frequent opportunities for sanitation.
As with previous editions of the event, the topics discussed and speakers involved have been updated and edited in an effort to reflect the changing of time and the rapid evolution of the field of regenerative medicine. That is why this symposium will focus on Cellular Therapies During and After the Pandemic. Coronavirus has changed life as we know it, but the scientific and medical communities have not stopped researching. In fact, cellular therapies have been an invaluable asset in managing the largest pandemic in modern history, due to their implications in treating respiratory failure and managing some of the complications induced by exposure to COVID-19. This has resulted in accelerated pathways for regulatory approval and increased funding for new regenerative medicine-based clinical trials, which will all be discussed in greater depth at the event.
But the Regenerative Medicine Symposium also provides a valuable networking opportunity for physicians in the Latin American community. “Here, people interested in cellular therapy can find everything they need to get on the right path to helping people with regenerative medicine,” Said Benito Novas, VP of Public Relations, ISSCA, “If you’ve done some research yourself, or really have no idea where to start– this would be the place. We’ve got vendors, instructors, and interview panels with several distinguished researchers,”
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.
The Global Stem Cells Group has at last finalized discussions to open a The Stem Cell Center Network site in Lisbon, portugal. The Stem Cell Center operates an international network of regenerative medicine practitioners that is dedicated to sharing information with the end goal of bringing cutting-edge regenerative medicine-based treatments to patients suffering from debilitating disease.
The new Portuguese Stem Cell Center will be comprised of a highly-accredited, state of the art clinic/laboratory manned by physicians and scientists with combined decades of experience. It will be another strong foothold in Iberia for the global company, and carries with it full license to use the Group’s proprietary treatment methods and branding designs.
This will be the Global Stem Cell Group’s first permanent location in Portugal, rounding out the company’s presence in Western Europe and the Portuguese-speaking market with the new Lisbon-based partnership. The Stem Cell Center Network continues to roll out new membership opportunities, programs, and events, and our membership has grown steadily year after year– To date, we are present in twenty five countries and five continents.
And to commemorate this partnership the Stem Cell Network has plans to open the clinic in September of 2020, and begin training physicians shortly after. “We’ve wanted to expand into Portugal for a very long time,” Said Benito Novas, Founder and CEO, Global Stem Cells Group, “Now that the world is tentatively opening up, it seemed like a good time to resume teaching physicians– after all, with more people getting sick, it is important for their doctors to have all the tools at their fingertips to help,”
Barring any extenuating circumstances, the Stem Cell Center Network remains scheduled to open in the first week of September, with bookings already being accepted for the Network’s inaugural training at this clinic. With limited availability due to current social distancing efforts, spots are filling up quickly, and prospective applicants are encouraged to sign up soon for the hands-on training course.
To Sign Up Today, Visit us At: www.issca.us
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.